The Impact of DEA Rescheduling on Canopy Growth, Tilray, and Cronos Group Stocks

Wednesday, 1 May 2024, 19:13

Investors drove marijuana stocks down today, cashing in after a previous surge. The rescheduling of marijuana as a Schedule III drug carries potential benefits but also new regulatory costs. Despite the sell-off, the future of the industry appears promising with legalization trends and increased profit potential.
https://store.livarava.com/f6840db3-07ef-11ef-a6c0-63e1980711b2.jpg
The Impact of DEA Rescheduling on Canopy Growth, Tilray, and Cronos Group Stocks

The great marijuana stock sell-off

Why are marijuana investors panicking today? Let's start with the obvious.

  • A Schedule III drug (such as ketamine, anabolic steroids or, soon, marijuana) may not be as strictly regulated...

Should you buy marijuana stocks?

If you ask me, the main reason marijuana stocks are selling off...

Despite today's sell-off, Canopy Growth, Tilray Brands, and Cronos Group stocks are still trading higher...


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe